Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 20, 2025
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results
GlobeNewswire
·
March 20, 2025
Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC Initiating new LINNET Phase 2 study of lorigerlimab in ovarian cancer Advancing multiple novel topoisomerase 1 inhibitor- …
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
GlobeNewswire
·
March 20, 2025
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with gross proceeds of …
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
GlobeNewswire
·
March 20, 2025
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust …
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 20, 2025
Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweight Faster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule; interim analysis removed Phase 2a dosing …
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
GlobeNewswire
·
March 20, 2025
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it …
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
GlobeNewswire
·
March 20, 2025
Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents …
Editas Medicine Announces Chief Financial Officer Transition
GlobeNewswire
·
March 20, 2025
Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today …
Solésence To Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call
GlobeNewswire
·
March 20, 2025
ROMEOVILLE, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the fourth …
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire
·
March 20, 2025
TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) Positive …
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
GlobeNewswire
·
March 20, 2025
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 …
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
GlobeNewswire
·
March 20, 2025
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the …
Spectral AI Announces Public Filing of Registration Statement for Proposed Initial Public Offering of Spectral IP
GlobeNewswire
·
March 20, 2025
DALLAS, March 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration in 2018 and uses …
Take the Lead: Forward a New Evolution in Slide-Free Pathology with MUSE Microscopy’s Groundbreaking SmartPath Technology
GlobeNewswire
·
March 20, 2025
IRVINE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- MUSE Microscopy, Inc., a pioneer in digital pathology innovation, is proud to announce the development of its revolutionary slide-free, digital tissue imaging platform. This cutting-edge technology is set …
Teclison, Inc. to Participate in Upcoming Investor Conference
GlobeNewswire
·
March 20, 2025
PRINCETON, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee, chief executive officer and co-founder of Teclison …
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
GlobeNewswire
·
March 20, 2025
Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company …
CURE Media Group and Oncology Nursing News® announce the 2025 Extraordinary Healer® award finalists and keynote speaker, Amy Robach
GlobeNewswire
·
March 20, 2025
CRANBURY, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- CURE Media Group and Oncology Nursing News® are pleased to announce the finalists for the 2025 Extraordinary Healer® award. This award honors oncology nurses whose compassion and expertise improve the …
PathAI Announces EMA Qualification for AIM-MASH AI Assist, a Groundbreaking AI Tool for MASH Clinical Trials
GlobeNewswire
·
March 20, 2025
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted full qualification for AIM-MASH AI …
Cylinder acquires Dieta Health, AI-powered stool imaging technology, to advance AI-driven digestive care
GlobeNewswire
·
March 20, 2025
CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Cylinder, the leading virtual digestive health provider, today announced its acquisition of Dieta Health, creator of the first clinically validated AI-powered stool imaging app. This acquisition will drive …
Beating the Clock: Melanoma Starts Evading Treatment Within Hours – Here’s How to Stop It
GlobeNewswire
·
March 20, 2025
SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes. The study, published in Cell Systems …
The Steadman Clinic’s Dr. Matthew T. Provencher Honored with the Prestigious Kappa Delta Ann Doner Vaughn Award
GlobeNewswire
·
March 20, 2025
VAIL, Colo., March 20, 2025 (GLOBE NEWSWIRE) -- Dr. Matthew T. Provencher, a distinguished orthopaedic surgeon specializing in complex knee and shoulder surgeries at The Steadman Clinic since his arrival in Vail nine years ago, has been awarded the …